Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.

Narikazu BokuTaroh SatohMin-Hee RyuYee ChaoKen KatoHyun Cheol ChungJen-Shi ChenKei MuroWon Ki KangKun-Huei YehTakaki YoshikawaSang Cheul OhLi-Yuan BaiTakao TamuraKeun-Wook LeeYasuo HamamotoJong Gwang KimKeisho ChinDo-Youn OhKeiko MinashiJae Yong ChoMasahiro TsudaTaihei NishiyamaLi-Tzong ChenYoon-Koo Kang

Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2021)

Long-term efficacy of nivolumab was confirmed at the 3-year follow-up, and a survival benefit of TBP with nivolumab was suggested. Biomarkers for selecting patients suitable for TBP with nivolumab should be identified in the future.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
squamous cell carcinoma
neoadjuvant chemotherapy
radiation therapy
patient reported
combination therapy